Discover
ITCI
Intra-Cellular Therapies, Inc.
131.87
undefined x undefined
undefined x undefined
bid
ask
+
131.87
0.00%
07:00 PM
| Ytd | 57.89% | |
| 1y | 97.80% |
day range
52 week range
| Open | Prev Close | Low | High | Mkt Cap | N/A | ||||
| Vol | 0.00 | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | 507.19 |
| Beta | 0.46 | Short Ratio | 1.20 | Inst. Own | 96.45% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 132.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-05-06 | 2025-03 | 0 | N/A | N/A | N/A |
| 2025-02-21 | 2024-12 | 0 | N/A | N/A | N/A |
| 2024-10-30 | 2024-09 | 0 | N/A | N/A | N/A |
| 2024-08-07 | 2024-06 | 0 | N/A | N/A | N/A |
| 2024-05-07 | 2024-03 | 0 | N/A | N/A | N/A |
| 2024-02-22 | 2023-12 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-04-02 | Cantor Fitzgerald | Upgrade | Neutral | Neutral |
| 2025-02-24 | Mizuho | Downgrade | Outperform | Neutral |
| 2025-02-21 | Needham | Upgrade | Hold | Hold |
| 2025-01-31 | Canaccord Genuity | Downgrade | Buy | Hold |
| 2025-01-22 | RBC Capital | Downgrade | Outperform | Sector Perform |
| 2025-01-14 | Piper Sandler | Downgrade | Overweight | Neutral |
Profile
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-03-09 | DURGAM SURESH K. | Officer | 42.91K | Conversion of Exercise of derivative security |
| 2025-03-09 | HALSTEAD MICHAEL I. | President | 21.31K | Conversion of Exercise of derivative security |
| 2024-03-10 | HINELINE LAWRENCE J | Chief Financial Officer | 0.00 | Sale |
| 2025-02-23 | MARCUS JOEL S | Director | 58.24K | Conversion of Exercise of derivative security |
| 2025-03-25 | MATES SHARON | Chief Executive Officer | 1.14M | Stock Gift |
| 2025-03-09 | NEUMANN MARK | Officer | 52.81K | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-12-30 | FMR, LLC | 11.08M | 1.46B | 10.40% |
| 2024-12-30 | Vanguard Group Inc | 9.72M | 1.28B | 9.13% |
| 2024-12-30 | Blackrock Inc. | 6.11M | 806.08M | 5.74% |
| 2024-12-30 | JPMORGAN CHASE & CO | 5.13M | 675.98M | 4.81% |
| 2024-12-30 | Wasatch Advisors LP | 3.25M | 428.42M | 3.05% |
| 2024-12-30 | NORGES BANK | 3.21M | 423.69M | 3.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17M | 417.79M | 2.97% |
| 2024-12-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.57M | 338.29M | 2.41% |
| 2024-12-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.49M | 196.78M | 1.40% |
| 2024-12-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.45M | 191.53M | 1.36% |
| 2024-12-30 | JPMorgan Trust II-JPMorgan Mid Cap Growth Fund | 1.31M | 172.75M | 1.23% |
| 2025-02-27 | Fidelity Contrafund | 1.20M | 158.83M | 1.13% |